Skip to main content
G

Guangdong Hybribio Biotech Co.,Ltd. — Investor Relations & Filings

Ticker · 300639 LEI · 655600IZO2GZ4A2SFO89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,529 across all filing types
Latest filing 2026-04-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300639

About Guangdong Hybribio Biotech Co.,Ltd.

https://www.hybribio.cn

Guangdong Hybribio Biotech Co.,Ltd. specializes in the research, development, and manufacturing of molecular diagnostic products and integrated laboratory services. The company is recognized for its proprietary flow-through hybridization technology, which serves as the foundation for its extensive range of diagnostic kits. Key product lines include Human Papillomavirus (HPV) genotyping assays for cervical cancer screening, as well as molecular tests for sexually transmitted infections, respiratory diseases, and neonatal genetic screening for conditions such as Thalassemia and G6PD deficiency. Hybribio provides automated nucleic acid extraction systems and real-time PCR platforms to facilitate high-throughput clinical diagnostics. Its solutions are utilized by medical institutions and public health programs to support early disease detection and personalized medicine through advanced molecular analysis.

Recent filings

Filing Released Lang Actions
关于2025年度计提资产减值准备的公告
Regulatory Filings Classification · 1% confidence The document is a standalone corporate announcement detailing the company’s provisioning for asset impairments for fiscal year 2025. It is not a full annual or interim report, earnings release, capital financing update, delisting notice, or any of the other specific categories. It is a regulatory‐required disclosure (公告) required by the Shenzhen Stock Exchange. It does not simply announce publication of a report but provides full details of the impairment provisions, so it falls under the miscellaneous regulatory filing category.
2026-04-28 Chinese
第六届董事会第五次会议决议公告
Board/Management Information Classification · 1% confidence The document is a public announcement of resolutions passed at the company’s Board of Directors meeting (the Sixth Board’s Fifth Meeting), detailing agenda items, voting results, and next steps. It is not the full annual report or financial statements, nor is it announcing a dividend or share issuance. It is clearly a board meeting resolution announcement, fitting the “Board/Management Information” category.
2026-04-28 Chinese
关于公司2025年度募集资金存放、管理与使用情况专项报告的鉴证报告
Audit Report / Information Classification · 1% confidence The document is a CPA’s verification (鉴证) report on the company’s 2025 fundraising capital deposit, management, and usage special report. It is a standalone audit/assurance report rather than a full annual or interim report, earnings release, dividend notice, or announcement. It fits the definition of an Audit Report / Information (AR).
2026-04-28 Chinese
上市公司非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 1% confidence The document is a tabular summary of non-operating funds occupancy and other related-party transactions for the 2025 fiscal year, approved by the board in April 2026. It is not a full annual or interim report, nor is it an audit opinion, earnings release, management/change notice, or any other specialized category. It also is not merely an announcement that a report is available but contains the substantive data itself. Therefore it best fits the fallback category for miscellaneous regulatory filings (RNS).
2026-04-28 Chinese
2025年年度报告摘要
Annual Report Classification · 1% confidence The document is titled “2025年年度报告摘要” (Annual Report Summary) and contains comprehensive financial statements (balance sheet, income, cash flows), business descriptions, shareholder tables, and audited opinions. It is the substantive summary of the company’s full annual report, not merely an announcement of publication. This aligns with the definition of an Annual Report (10-K). FY 2025
2026-04-28 Chinese
2025年度独立董事述职报告（陈英实）
Governance Information Classification · 1% confidence The document is not an annual or interim financial report, earnings release, or notice of corporate actions, but rather a detailed report by an independent director on governance and compliance activities over the year. It focuses on board attendance, committee work, internal control, audit committee reviews, and corporate governance oversight. This aligns with Governance Information (CGR): reports detailing board structure, governance practices, and related procedures. It is not merely an announcement or proxy solicitation, so CGR is most appropriate.
2026-04-28 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.